GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback